Boundless Bio, Inc. (BOLD) Stock Profile — Insider Trades & Financials

Net Income-$12.9M

EPS$-2.03

Market Cap$25.8M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Zachary Hornby

CEO & Executive Director

Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype. The company was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. Boundless Bio, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Founded: 2018
Employees: 28
Headquarters: San Diego, California, United States

⚡

Core Efficiency

ROE?

-13.06%

ROA?

-8.20%

D/E Ratio?

0.59

📊

Profitability Ratios

Current Ratio?

8.74

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Aug 1, 2026 (in 114 days)

Annual Report (10-K) — Based on filing pattern

Aug 1, 2026

Predicted10-K

Mar 9, 2026

10-KQ4 20257d after period end

Nov 5, 2025

10-QQ3 20255d after period end

Aug 5, 2025

10-QQ2 20255d after period end

May 9, 2025

10-QQ1 20253d after period end

Mar 27, 2025

10-KQ4 20246d after period end

Nov 7, 2024

10-QQ3 20241d after period end

Aug 12, 2024

10-QQ2 202412d after period end

May 13, 2024

10-QQ1 20247d after period end

Loading company sections...

Boundless Bio, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness